EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Isoniazid preventive therapy during infancy does not adversely affect growth among HIV-exposed uninfected children: Secondary analysis of data from a randomized controlled trial

Ashenafi Shumey Cherkos iD, Sylvia M LaCourse, Daniel A Enquobahrie, Jaclyn N Escudero, Jerphason Mecha, Daniel Matemo, John Kinuthia, Sarah J Iribarren, Grace John-Stewart iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0293708 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Ashenafi Shumey Cherkos und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population and Community Health, School of Public Health, University of North Texas Health Science Center, Fort Worth, Texas, United St…. Hauptthemen laut MEDLINE: Isoniazid, Antitubercular Agents, HIV Infections, Tuberculosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, FIC NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Isoniazid preventive therapy (IPT) decreases risk of tuberculosis (TB) disease; impact on long-term infant growth is unknown. In a recent randomized trial (RCT), we assessed IPT effects on infant growth without known TB exposure.

Methods

The infant TB Infection Prevention Study (iTIPS) trial was a non-blinded RCT among HIV-exposed uninfected (HEU) infants in Kenya. Inclusion criteria included age 6–10 weeks, birthweight ≥2.5 kg, and gestation ≥37 weeks. Infants in the IPT arm received 10 mg/kg isoniazid daily for 12 months, while the control trial received no intervention; post-trial observational follow-up continued through 24 months of age. We used intent-to-treat linear mixed-effects models to compare growth rates (weight-for-age z-score [WAZ] and height-for-age z-score [HAZ]) between trial arms.

Results

Among 298 infants, 150 were randomized to IPT, 47.6% were females, median birthweight was 3.4 kg (interquartile range [IQR] 3.0–3.7), and 98.3% were breastfed. During the 12-month intervention period and 12-month post-RCT follow-up, WAZ and HAZ declined significantly in all children, with more HAZ decline in male infants. There were no growth differences between trial arms, including in sex-stratified analyses. In longitudinal linear analysis, mean WAZ (β = 0.04 [95% CI:-0.14, 0.22]), HAZ (β = 0.14 [95% CI:-0.06, 0.34]), and WHZ [β = -0.07 [95% CI:-0.26, 0.11]) z-scores were similar between arms as were WAZ and HAZ growth trajectories. Infants randomized to IPT had higher monthly WHZ increase (β to 24 months 0.02 [95% CI:0.01, 0.04]) than the no-IPT arm.

Conclusion

IPT administered to HEU infants did not significantly impact growth outcomes in the first two years of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsoniazidAntitubercular AgentsHIV InfectionsTuberculosisHumansFemaleInfantMaleKenyaChild, PreschoolInfant, Newborn

Substanzen

IsoniazidAntitubercular Agents

Autor:innen und Institutionen

  • Department of Population and Community Health, School of Public Health, University of North Texas Health Science Center, Fort Worth, Texas, United States of America.
  • Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, United States of America.
  • Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, United States of America.
  • Department of Global Health, School of Public Health, University of Washington, Seattle, Washington, United States of America.
  • Centre for Respiratory Diseases Research, Kenya Medical Research Institute, Nairobi, Kenya.
  • Medical Research Department, Kenyatta National Hospital, Nairobi, Kenya.

ORCID-Profile: Ashenafi Shumey Cherkos, Grace John-Stewart

Förderung

  • NIAID NIH HHS
  • FIC NIH HHS
  • NCATS NIH HHS
  • Thrasher Research Fund
  • NIH/NIAID
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Cherkos, A. S., LaCourse, S. M., Enquobahrie, D. A., Escudero, J. N., Mecha, J., Matemo, D., Kinuthia, J., Iribarren, S. J., & John-Stewart, G. (2024). Isoniazid preventive therapy during infancy does not adversely affect growth among HIV-exposed uninfected children: Secondary analysis of data from a randomized controlled trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0293708

Vancouver

Cherkos AS, LaCourse SM, Enquobahrie DA, Escudero JN, Mecha J, Matemo D, et al. Isoniazid preventive therapy during infancy does not adversely affect growth among HIV-exposed uninfected children: Secondary analysis of data from a randomized controlled trial. PLOS ONE. 2024. doi:10.1371/journal.pone.0293708

BibTeX
@article{Cherkos2024,
  author = {Cherkos, Ashenafi Shumey and LaCourse, Sylvia M and Enquobahrie, Daniel A and Escudero, Jaclyn N and Mecha, Jerphason and Matemo, Daniel and Kinuthia, John and Iribarren, Sarah J and John-Stewart, Grace},
  title = {Isoniazid preventive therapy during infancy does not adversely affect growth among HIV-exposed uninfected children: Secondary analysis of data from a randomized controlled trial},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0293708}
}
Kostenlos starten →